Literature DB >> 3027386

Laboratory production in vivo of infectious human papillomavirus type 11.

J W Kreider, M K Howett, A E Leure-Dupree, R J Zaino, J A Weber.   

Abstract

Human papillomaviruses (HPV) induce among patients natural lesions which produce small amounts of virus. Infection of human cell cultures does not lead to the multiplication of virus, which also does not replicate in experimental animals. We have developed a unique system for the laboratory production of HPV type 11 (HPV-11). Fragments of human neonatal foreskin were infected with an extract of naturally occurring human vulvar condylomata and grafted beneath the renal capsule of athymic mice. Later (3 to 5 months), condylomatous cysts developed from those grafts. Nuclei of koilocytotic cells contained large amounts of capsid antigen and intranuclear virions. The experimentally induced condylomata were homogenized, and the virions were extracted and used to infect another generation of human foreskin grafts in athymic mice. The HPV-11 DNA content and infectivity of the natural and experimental condylomata were similar. Extracts of experimental condylomata were subjected to differential ultracentrifugation and sedimentation in CsCl density gradients. A single, opalescent band was visible at a density of 1.34 g/ml. It contained HPV virions with HPV-11 DNA. This report is the first demonstration of the laboratory production of an HPV.

Entities:  

Mesh:

Year:  1987        PMID: 3027386      PMCID: PMC253985          DOI: 10.1128/JVI.61.2.590-593.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  7 in total

1.  Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene.

Authors:  M Grunstein; D S Hogness
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  Fractionation of Shope papilloma virus in cesium chloride density gradients.

Authors:  C BREEDIS; L BERWICK; T F ANDERSON
Journal:  Virology       Date:  1962-05       Impact factor: 3.616

3.  Morphological characterization of the virus of the human common wart (verruca vulgaris).

Authors:  M G WILLIAMS; A F HOWATSON; J D ALMEIDA
Journal:  Nature       Date:  1961-03-18       Impact factor: 49.962

4.  In vivo transformation of human skin with human papillomavirus type 11 from condylomata acuminata.

Authors:  J W Kreider; M K Howett; N L Lill; G L Bartlett; R J Zaino; T V Sedlacek; R Mortel
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Immunologic relatedness of papillomaviruses from different species.

Authors:  A B Jenson; J D Rosenthal; C Olson; F Pass; W D Lancaster; K Shah
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

6.  Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata.

Authors:  J W Kreider; M K Howett; S A Wolfe; G L Bartlett; R J Zaino; T Sedlacek; R Mortel
Journal:  Nature       Date:  1985 Oct 17-23       Impact factor: 49.962

7.  Correlation between content of viral DNA and evidence of mature virus particles in HPV-1, HPV-4, and HPV-6 induced virus acanthomata.

Authors:  E I Grussendorf-Conen; L Gissmann; J Hölters
Journal:  J Invest Dermatol       Date:  1983-12       Impact factor: 8.551

  7 in total
  41 in total

1.  Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.

Authors:  Timothy D Culp; Lynn R Budgeon; M Peter Marinkovich; Guerrino Meneguzzi; Neil D Christensen
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

3.  Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle.

Authors:  E R Flores; P F Lambert
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 5.  [Prophylactic and therapeutic HPV immunization].

Authors:  M Müller; L Gissmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 6.  Cancer of the cervix: prospects for immunological control.

Authors:  D H Davies; G A McIndoe; B M Chain
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

7.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

8.  Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Diagnosis of genital infection caused by human papillomavirus using in situ hybridisation: the importance of the size of the biopsy specimen.

Authors:  F Gómez; M T Corcuera; E Muñoz; M Roldan; M J Alonso; M Abad; J I Paz; A López-Bravo
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

10.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.